Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study is aimed to evaluate efficacy and safety of dienogest 2 mg oral tablets in the
treatment of endometriosis.
There will be 2 study phases: a double-blind, randomized, placebo-controlled, parallel-group
phase over 24 weeks, and an open-label extension phase with 2 mg DNG daily p.o. over 28 weeks
for all subjects who completed the double-blind phase, irrespective of their treatment
assignment in the first study phase.